Evan Masingill
GenBioPro, which manufactures only the abortion medications mifepristone and misoprostol, has a 'North Star' that guides its work, Masingill says: reproductive freedom for all people. Masingill says the company's tagline since it was launched in 2012 is 'putting access into practice.' And GenBioPro has committed to that core value. In 2019, the company obtained approval from the U.S. Food and Drug Administration (FDA) to sell the first generic mifepristone tablet in the U.S., which GenBioPro said 'has helped stabilize supply and satisfy the rising demand among patients for medical abortion.' Medication abortion is the most common method of abortion in the U.S. and has become essential for people living in states where abortion is banned or restricted.
GenBioPro is now fighting to protect access to its products. In February, GenBioPro asked a Texas court to include the company as a defendant in a lawsuit filed by state attorneys general from Missouri, Idaho, and Kansas that is seeking to roll back a series of FDA policies implemented during the Biden Administration that have facilitated access to medication abortion. One change the state attorneys general are seeking, for instance, is reinstating the requirement that mifepristone be dispensed in person rather than by mail. In October, GenBioPro urged a federal appeals court to side with it in a lawsuit it filed against West Virginia in 2023 over the state's near-total abortion ban, arguing that the FDA's approval of abortion pills supersedes the state's ban.
Masingill says this work is necessary and that there will always be people in power who try to restrict access to care.
'Does it grind my gears or get me heated?' he says. 'Of course. Is it sad? Yeah. But that doesn't mean we can't do anything.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
31 minutes ago
- Yahoo
Over 100,000 Ice Cream Bars Recalled For Listeria Risk—Here's What You Need To Know
The bars were sold in 23 states. If you've been trying to beat the summer heat with sweet treats, you may want to check the package. Rich's Ice Cream is recalling some of its frozen novelties due to potential listeria contamination. The Food and Drug Administration Authority (FDA) announced that the Florida-based company is working with them to recall the products, which were distributed across the country. The ice cream treats affected by the recall include some of Rich's most popular novelties, including their Savagely Sour Bars, Chocolate Crunch Cake Bars, Strawberry Shortcake Bars, Rich Bars, Orange Cream Bars, Cool Watermelon Bars, Fudge Frenzy Bars, and more. According to the FDA, there are potentially 110,292 cases affected. The bars were sold in 23 states, including those across the South: Alabama Georgia Florida Texas Virginia Tennessee South Carolina Oklahoma Louisiana For a full list of states where the potentially contaminated products were distributed, head to the FDA's website. To find out if the ice cream in your freezer is part of the recall, look on the package for lot numbers 24351 through lot 25156. As USA Today notes, the recall was initiated with the FDA on June 27, and it is classified as Class II recall. That is "a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote," the FDA website states. Listeria contamination is potentially serious. It is exceptionally dangerous for pregnant women, newborns, older adults, and people with weakened immune systems, per the U.S. Centers for Disease Control and Prevention. If you are still hankering for something sweet, here's how to make homemade ice the original article on Southern Living Solve the daily Crossword
Medscape
5 hours ago
- Medscape
FDA Declines to Approve New Melanoma Therapy
The FDA has declined to approve a new oncolytic immunotherapy, vusolimogene oderparepvec (RP1), to treat advanced melanoma. The agency recently issued a complete response letter to the company, Replimune Group, rejecting its biologics license application that sought approval for the new agent in combination with nivolumab (Opdivo) to treat adults with advanced melanoma. In the complete response letter, the FDA indicated that it can't approve the biologics license application for vusolimogene oderparepvec because the company's IGNYTE trial 'is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness,' Replimune explained in a press release. According to Replimune, the complete response letter also noted that the trial data 'cannot be adequately interpreted due to the heterogeneity of the patient population,' and that 'there are items related to the confirmatory trial study design which need to be addressed.' 'We are surprised by the FDA decision and disappointed for advanced melanoma patients who have limited treatment options, as highlighted by the granting of breakthrough status at the time we provided the IGNYTE primary data,' stated Sushil Patel, PhD, Replimune's chief executive officer. Vusolimogene oderparepvec is the lead product candidate for the biotech company. Patel further noted that the issues raised in the complete response letter were not 'raised by the agency in mid- and late-cycle reviews.' Additionally, he said, 'we had also aligned on the design of the confirmatory study.' The FDA's response to the biologics license application for the new agent, along with its recently announced policy requiring randomized, controlled trials for approval of COVID vaccines in healthy Americans younger than 65 years, may signal that the agency is taking a tougher stance on new drug approvals. Replimune plans to 'urgently interact with the FDA to find a path forward for the timely accelerated approval of RP1,' according to its statement. Sharon Worcester, MA, is an award-winning medical journalist based in Birmingham, Alabama, writing for Medscape Medical News, MDedge, and other affiliate sites. She currently covers oncology, but she has also written on a variety of other medical specialties and healthcare topics. She can be reached at sworcester@ or on X @SW_MedReporter.
Newsweek
11 hours ago
- Newsweek
Canned Fruit Recall Sparks Nationwide Warning to Customers
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. W.W. Industrial Group is recalling Parashore brand pear slices in juice due to fears the product may contain elevated levels of lead and cadmium. Newsweek reached out to the company via phone Wednesday for comment and left a voicemail. Why It Matters Elevated levels of lead and cadmium can cause significant health problems, particularly among infants and children. The recall adds to a growing list of high-profile food safety actions, emphasizing the ongoing importance of vigilant federal oversight and thorough product testing to protect public health. Lead and cadmium are both toxic metals that can enter the food supply from environmental sources, such as contaminated soil or industrial byproducts. According to the U.S. Food and Drug Administration (FDA), lead exposure poses particular risks to young children, whose developing brains are highly susceptible to neurotoxic effects. Elevated lead intake in early childhood has been linked to long-term issues affecting learning and behavior. Cadmium contamination can arise from soil composition, industrial activities and certain manufacturing processes. Prolonged exposure to cadmium, especially at levels above the FDA's interim reference level, can affect kidney function and increase the risk of bone demineralization. While it is not possible to completely prevent cadmium from entering the food supply, manufacturers are legally required to minimize and monitor such risks. Numerous recalls have been initiated in 2025 due to the potential for damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the FDA, the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. What To Know In the FDA alert, the recalled sliced pears were distributed throughout grocery outlet stores in California and other locations across the United States. The products were sold in a 15-ounce can with a UPC number of #704817164237. "The specific lot found positive for heavy metals was Lot 3700/01172 6122J, Prod: 02/19/2024, Best by 2/19/2027," the FDA warns. The agency adds that there had been no reported illnesses related to the recall as of Tuesday. What People Are Saying The FDA alert, in part: "The heavy metal contamination was discovered via sampling by the Maryland Department of Health which is part of the FDA Laboratory Flexible Funding Model program. The company has recalled the products and is continuing an investigation to determine cause." What Happens Next Customers who have purchased the recalled pear slices are urged to throw them away or return the product to the original place of purchase for a full refund, the FDA says. People with additional questions can contact W.W. Industrial Group via phone at 516- 676-9188 from 10 a.m. to 4 p.m. ET weekdays.
